Drugs Affecting Lipid Metabolism
Springer (Verlag)
978-94-010-4746-3 (ISBN)
1. Regression of Human Aortic Fatty Streaks of Early Life.- 2. Serum Cholesterol as — Risk Factor: Effects of Gender and Age.- 3. Influence of Atherogenic Lipoproteins on the Thrombotic Potential of Endothelial Cells.- 4. Plurimetabolic Syndrome or Syndrome X. Is it — Real Syndrome?.- 5. Three Liver-Enriched Transcription Factors: HNF-1, C/EBP, and Protein II are Required to Enhance Transcription of the Human Apolipoprotein.- 6. Structure-Function Relationships of Apolipoprotein B-100.- 7. Contribution of Helix-Helix Interactions to the Stability of Apolipoprotein-Lipid Complexes.- 8. Oxidatively Modified LDL and Atherosclerosis.- 9. Postprandial Hyperlipidemia and Coronary Artery Disease.- 10. Genetic Factors Affecting Lipoprotein Metabolism.- 11. Lipoprotein Assembly: — Potential Target for Drugs Affecting Lipid Metabolism.- 12. Structural Features that Determine the Functional Properties of the Loop Region of Human Lipoprotein Lipase.- 13. Molecular Genetics of Lipoprotein Lipase Deficiency.- 14. — New Case of Lipoprotein Lipase Deficiency.- 15. Modulation of Triglyceride Metabolism by Diet and Drugs.- 16. Drugs Affecting Reverse Cholesterol Transport.- 17. High Density Lipoproteins: Function in Reverse Cholesterol Transport and Maintenance of Cellular Integrity.- 18. The Expression and Regulation of Cholesterol 7?- Hydroxylase.- 19. Cholesterol Metabolism in Normo and Genetically Hyperlipidemic Rats in Aging.- 20. In Vitro Effect of Thiol- and Cysteine-Containing Compounds on the Immunological Reactivity of Human and Rhesus Monkey Lipoprotein(a).- 21. The Interaction of Lp(a) with Liver Cells: Implications for Lipid Lowering Therapy.- 22. Metabolism of Apo(a) and ApoB-100 in Human Lipoprotein(a).- 23. Vitamin E-Absorption, Transport in Lipoproteins,Delivery to Tissues and Antioxidant Activity.- 24. Role of the Macrophage Scavenger Receptor in the 9-Hydroxy-Octadecadienoic Acid Mediated Expression of Interleukin 1?.- 25. Oxidative Damage to Circulating LDL.- 26. Dietary Advice for the Prevention of Arterial Thrombosis.- 27. Drugs Affecting High-Density Lipoprotein and Triglyceride Metabolism.- 28. Drugs Affecting Thrombosis and Atherosclerosis.- 29. Lipid Lowering: Progression and Regression of Atherosclerotic Lesions.- 30. Clinical Trials of Atherosclerosis Regression.- 31. Biochemical Mechanisms Associated with the Lipolytic Effects of Calcium Channel Blockers.- 32. Pravastatin Reduces Plasma Concentration of — More Electronegatively Charged LDL Subtraction in FH.- 33. Clinical Experience with Fluvastatin, the First Synthetic HMG-CoA Reductase Inhibitor.- 34. Secondary Prevention of Cardiovascular Disease: The Role of HMG-CoA Reductase Inhibitors.- 35. Combined Drug Treatment of Severe Hypercholesterolemia.- 36. Regression of Coronary Atherosclerosis by LDL-Apheresis.- 37. Partial Ileal Bypass — Results of the Program on the Surgical Control of the Hyperlipidemias (POSCH).- 38. Hypercholesterolemia: Negotiating the Issues.- 39. Antiatherosclerotic Drugs: — Critical Assessment.- 40. Experimental and Clinical Evidence for — Protective Role of High-Density Lipoprotein in Coronary Heart Disease.- 41. HDL as — Risk Factor for Coronary Heart Disease: An Update on the Helsinki Heart Study.- 42. Relationship of HDL Cholesterol to Incidence of Atherosclerotic Coronary Heart Disease: The PROCAM Experience.- 43. The Clinical Approach to the Patients with Low HDL and Elevated Plasma Triglyceride.- 44. Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease.- 45. Efficacy of Fenofibrateon Plasma Cholesterol in Swine with Spontaneous Hypercholesterolemia.- 46. Lipoprotein Particles Heterogeneity: Clinical and Pharmacological Implication.- 47. Fibrinogen: Pathogenetical and Therapeutical Implications in Atherosclerosis.- 48. Regression and Decrease in Progression of Coronary Artery Disease Through Lipid-Lowering Therapy.- 49. Glycation and Oxidation of Proteins: — Role in the Pathogenesis of Atherosclerosis?.- 50. — Modern View of Atherogenesis.- 51. Defective Catabolism of Oxidized LDL by J774 Murine Macrophages.- 52. Analysis of Lipid vs. Non-Lipid Effect on Atherosclerosis Development.- 53. Atherogenicity of Triglyceride-Rich Lipoproteins: Cellular Aspects.- 54. Atherogenicity of Triglyceride-Rich Lipoproteins: Clinical Aspects.- 55. Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia.- 56. Effects of Fibrates on the Altered Lipoprotein System in Hypertriglyceridemia.- 57. Triglyceride-Rich Lipoproteins: Role in Atherogenesis and Haemostasis.- 58. The Role of Plasma Membrane Cholesterol Pools in the Regulation of Cellular Cholesterol Efflux.- 59. Kinetics of Exogenous Di-Linoleyl Phosphatidylcholine and Incorporation in Plasma and RBC Lipids in Man.- 60. Alimentary Lipemia and Phospholipids.
Reihe/Serie | Medical Science Symposia Series ; 2 |
---|---|
Zusatzinfo | XX, 520 p. |
Verlagsort | Dordrecht |
Sprache | englisch |
Maße | 160 x 240 mm |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie |
ISBN-10 | 94-010-4746-4 / 9401047464 |
ISBN-13 | 978-94-010-4746-3 / 9789401047463 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich